Search

Displaying results 6331 - 6340 of 6831 in total
  1. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...

  2. Drug

    Fluasterone

    go.drugbank.com/drugs/DB06250
    Experimental

    Has antiproliferative effects on HIV-1 and reduces HIV-1 replication.

  3. Drug

    G4544

    go.drugbank.com/drugs/DB05244
    Experimental

    G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabo...

  4. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.

  5. Drug

    MD05

    go.drugbank.com/drugs/DB06375
    Investigational

    MD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).

  6. Drug

    Vasomera

    go.drugbank.com/drugs/DB16498
    Investigational

  7. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...

  8. Drug

    PR-104

    go.drugbank.com/drugs/DB05968
    Investigational

  9. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  10. Drug

    VA-MENGOC-BC®

    go.drugbank.com/drugs/DB15800
    Experimental

    Novel antigens such as γ-glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein were also identified with administration of this vaccine by a study.